BioCentury
ARTICLE | Clinical News

Epizyme gains on tazemetostat data

June 23, 2015 1:38 AM UTC

Epizyme Inc. (NASDAQ:EPZM) jumped $5.23 (25%) to $25.98 on Monday after it reported data from an ongoing Phase I dose-escalation study of cancer compound tazemetostat ( EPZ-6438) that showed objective responses in blood cancer patients.

Nine of 15 evaluable tazemetostat patients with relapsed non-Hodgkin's lymphoma (NHL) had an objective response. Among them, five of nine subjects with diffuse large B cell lymphoma (DLBCL) had an OR, three of five patients with follicular lymphoma had an OR, and one patient with marginal zone lymphoma (MZL) had a partial response. ...